Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression
- 11 May 2023
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 640, 123043
Abstract
No abstract availableKeywords
This publication has 125 references indexed in Scilit:
- Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy EfficiencyAdvanced Science, 2022
- Rebaudioside A/TPGS mixed nanomicelles as promising nanocarriers for nimodipine ocular deliveryDrug Delivery and Translational Research, 2020
- Incidence and Survival of Patients With Conjunctival Melanoma in EuropeJAMA Ophthalmology, 2020
- Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival MelanomaJAMA Ophthalmology, 2018
- Pembrolizumab for Recurrent Conjunctival MelanomaJAMA Ophthalmology, 2017
- An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy, 2011
- Wnt pathway-related gene expression during malignant progression in ulcerative colitisActa Histochemica, 2007
- Conjunctival MelanomaRisk Factors for Recurrence, Exenteration, Metastasis, and Death in 150 Consecutive PatientsArchives of Ophthalmology (1950), 2000
- The National Cancer Data Base report on cutaneous and noncutaneous melanomaCancer, 1998
- Surgical Management of Conjunctival TumorsArchives of Ophthalmology (1950), 1997